Drug intelligence / Profile preview

RD2202

Development stage: Preclinical
Lead developer: Pharmgen Science
Modality: Small Molecules
Administration: Oral

Overview

RD2202 is a small molecule therapeutic candidate being developed by the South Korean pharmaceutical company Pharmgen Science. The program is specifically focused on the treatment of acute and chronic gastritis through dosage-form improvement. This classification typically involves optimizing the delivery, stability, or bioavailability of a known active pharmaceutical ingredient to improve clinical outcomes, safety, or patient adherence. As of 2024, the project is in the development phase within Pharmgen Science's internal R&D pipeline, aimed at enhancing the company's gastrointestinal product portfolio.

Targets

MUC5AC (Mucin-5AC)

Beyond the preview

Go deeper on RD2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RD2202.

Explore the full profile